Key result
Pulmonary lymphangitic carcinomatosis in patients with gynecologic cancer resulted in extremely poor survival, with a mean survival time of 5.7 months from diagnosis to death.
Why the study?
Pulmonary lymphangitic carcinomatosis is a rare metastatic event in advanced gynecologic malignancy where nonspecific symptoms and detection difficulties often delay diagnosis, prompting evaluation of clinical outcomes.
Cohort (n=27)
No
Pulmonary lymphangitic carcinomatosis in gynecologic malignancy is associated with extremely poor survival, averaging 5.7 months from diagnosis to death.
Answers are grounded in this paper and cite their sources.
PLC portends dismal survival in gynecologic cancers; hypothesis-generating for earlier detection strategies and novel therapies.
OBJECTIVE: Pulmonary lymphangitic carcinomatosis (PLC) is a rare event of metastatic lung disease in advanced gynecologic malignancy. Nonspecific symptoms of patients and difficulties in detection of PLC often result in a delayed diagnosis. In this study, we evaluated the clinical outcomes of PLC in patients with gynecologic cancer. MATERIALS AND METHODS: We retrospectively reviewed electronic medical records of patients with gynecologic cancer who received care from January 1, 2008 through December 31, 2018 in Samsung Medical Center, Seoul, Republic of Korea. We based diagnosis of PLC on chest CT scan and analyzed clinical parameters of cancer type, International Federation of Gynecology and Obstetrics (FIGO) stage, histology, and patient survival. RESULTS: During the study period, 27 cases of PLC in patients with gynecologic malignancy were identified, including 11 cervical, 12 ovarian, and four uterine cancers. The most common histologic type at initial diagnosis was squamous cell in cervical (6/11, 55%), serous in ovarian (1/11, 92%), and serous in endometrial (2/4, 50%) cancer. The average survival time from diagnosis of PLC to death was a mean of 5.7 months (0.7-23.6 months) in all patients and 6.3, 6.6, and 3.6 months for cervical, endometrial, and ovarian cancer, respectively. CONCLUSION: This study showed that PLC results in extremely poor survival, from several days to a few months, in patients with gynecologic cancer. Clinicians must be aware of these clinical characteristics and consider other novel therapeutic strategies in the future.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2022) conducted a cohort in Pulmonary lymphangitic carcinomatosis in gynecologic malignancy (n=27). Pulmonary lymphangitic carcinomatosis was evaluated on Survival time from diagnosis of PLC to death. Pulmonary lymphangitic carcinomatosis in patients with gynecologic cancer resulted in extremely poor survival, with a mean survival time of 5.7 months from diagnosis to death.
Synapse has enriched 10 related papers. Consider them for comparative context: